Does low IgA weaken mucosal immune exclusion while stool zonulin family peptide fails to assess intestinal permeability?

The intestinal mucosal barrier relies on a dual-defense system: immunological exclusion at the luminal surface and a physical epithelial seal regulated by tight junctions.

Clinical and diagnostic evidence

• Immunological exclusion: Secretory IgA (sIgA) is the primary molecular mediator that traps, agglutinates, and clears luminal pathogens and dietary antigens. A deficiency in sIgA directly compromises this protective front-line shield, allowing intact antigens to freely access the epithelial surface.
• Stool zonulin invalidity: Commercial stool "zonulin family peptide" (ZFP) assays are clinically invalid for assessing intestinal permeability. Due to a profound lack of analytical specificity, these enzyme-linked immunosorbent assays (ELISAs) capture unrelated complement proteins (such as properdin and complement factor C3) rather than canonical pre-haptoglobin 2 (pre-HP2). Consequently, stool ZFP levels do not correlate with the gold-standard lactulose-mannitol (L/M) fractional excretion test.

Mechanistic pathways of immune activation

• Antigen translocation: When mucosal exclusion fails or tight junctions (regulated by claudins, occludins, and zonula occludens-1) degrade, macromolecular antigens like bacterial lipopolysaccharides (LPS) and food proteins cross into the lamina propria via paracellular pathways.
• Inflammatory cascade: These translocated antigens engage pattern-recognition receptors (such as Toll-like receptor 4) on resident immune cells. This activates the NF-κB transcription pathway, driving the release of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) and promoting Th17-mediated chronic inflammation.
• Feed-forward loop: The resulting local and systemic inflammatory cytokines feedback to downregulate tight junction proteins, further worsening barrier permeability and perpetuating a pathological cycle of antigen exposure.

Bottom line

• While low secretory IgA and increased physical tight junction permeability directly drive chronic local and systemic inflammation, commercial stool zonulin family peptide (ZFP) testing is highly non-specific and cannot be used to clinically diagnose or monitor intestinal barrier dysfunction.